AstraZeneca is expanding its partnership with Israel’s Immunai (see here previously), deepening its use of Immunai’s AMICA-OS artificial intelligence platform in oncology treatment development. Immunai will be eligible to receive up to $37.5 million during 2026 and 2027.

https://www.calcalistech.com/ctechnews/article/bkhaclqcwe